78 related articles for article (PubMed ID: 17724741)
21. International pharmaceutical social risk regulation: An ethical perspective.
Gordon C
Acta Pharm; 2011 Mar; 61(1):15-23. PubMed ID: 21406340
[TBL] [Abstract][Full Text] [Related]
22. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation.
Ball D; Blanchard J; Jacobson-Kram D; McClellan RO; McGovern T; Norwood DL; Vogel W; Wolff R; Nagao L
Toxicol Sci; 2007 Jun; 97(2):226-36. PubMed ID: 17369604
[TBL] [Abstract][Full Text] [Related]
23. The business case for patient safety.
Hwang RW; Herndon JH
Clin Orthop Relat Res; 2007 Apr; 457():21-34. PubMed ID: 17259896
[TBL] [Abstract][Full Text] [Related]
24. Communicating the risks and benefits of medicines.
Schmid EF; Smith DA; Ryder SW
Drug Discov Today; 2007 May; 12(9-10):355-64. PubMed ID: 17467571
[TBL] [Abstract][Full Text] [Related]
25. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological mechanism-based drug safety assessment and prediction.
Abernethy DR; Woodcock J; Lesko LJ
Clin Pharmacol Ther; 2011 Jun; 89(6):793-7. PubMed ID: 21490594
[TBL] [Abstract][Full Text] [Related]
27. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacovigilance: theoretical and practical aspects].
Paoletti V; Galeotta G; Mammarella A
Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
30. Regulation of biotechnology products in the global pharmaceutical market: the case of the European community and the United States.
Hakim Z; Kucukarslan S
Clin Ther; 1993; 15(2):442-58; discussion 432. PubMed ID: 8519050
[TBL] [Abstract][Full Text] [Related]
31. The identification of benefit in medical intervention: an overview and suggestions for process.
Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
[TBL] [Abstract][Full Text] [Related]
32. The science of health technology assessment: the safety perspective.
Shear NH
Can J Clin Pharmacol; 2001; 8 Suppl A():24A-28A. PubMed ID: 11586375
[TBL] [Abstract][Full Text] [Related]
33. Big pharma and health care: unsolvable conflict of interests between private enterprise and public health.
Brezis M
Isr J Psychiatry Relat Sci; 2008; 45(2):83-9; discussion 90-4. PubMed ID: 18982834
[TBL] [Abstract][Full Text] [Related]
34. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
35. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.
Allan MC
J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649
[TBL] [Abstract][Full Text] [Related]
36. [Drug surveillance within the pharmaceutical industry: present and future].
Soto J; Sacristán JA; Alsar MJ; Galende I
Med Clin (Barc); 1996 May; 106(17):665-9. PubMed ID: 8691914
[No Abstract] [Full Text] [Related]
37. A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry.
Quartey G; Wang J; Kim J
Pharm Stat; 2011; 10(6):548-53. PubMed ID: 22127819
[TBL] [Abstract][Full Text] [Related]
38. Proactive safety surveillance.
Bortnichak EA; Wise RP; Salive ME; Tilson HH
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):191-6. PubMed ID: 11501330
[TBL] [Abstract][Full Text] [Related]
39. The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety.
Woo J; Wolfgang S; Batista H
Clin Pharmacol Ther; 2008 Mar; 83(3):494-7. PubMed ID: 18253142
[TBL] [Abstract][Full Text] [Related]
40. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
Hilmer SN; Gnjidic D; Abernethy DR
J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
